Compare Stanley Black & Decker, Inc. (SWK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Stanley Black & Decker, Inc. trades at $90.89 (market cap $13.64B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Stanley Black & Decker, Inc. is far larger — about 2.7× Travere Therapeutics Inc. Common Stock's market cap, and Stanley Black & Decker, Inc. pays a 3.72% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stanley Black & Decker, Inc. for 62 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SWK | TVTX | |
|---|---|---|
Market Cap | $13.64B | $5.02B |
Volume | 1,097,590 | 2,060,842 |
Sector | Industrials | Health |
52-Week High | $104.00 | $67.52 |
52-Week Low | $62.12 | $26.79 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $17.80B | $5.15B |
Dividend Yield | 3.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $90.71, up 2.32% today, with a bearish technical signal despite recent earnings beats. The stock shows modest valuation with a P/E of 22.08 and P/S of 0.9, while profitability metrics like net income margin of 4.07% and ROE of 6.89% reflect steady improvement. Recent news highlights product launches and dividend payments, with the company targeting margin gains and market share growth for its DEWALT brand.
The outlook is mixed; analyst consensus leans hold with a $93 price target, but operational execution and cost savings provide upside potential. Risks include competitive pressures and macroeconomic headwinds, though institutional buying and a 200+ year dividend history support long-term stability. Earnings growth remains the key catalyst for further upside.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
